Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-α treatment in patients with malignant melanoma: Results from the multicenter DeCOG trial

Journal of Immunotherapy

Volumn 33, Issue 1, 2010, Pages 106-114

  Heinze, Sarah ^a   Egberts, Friederike ^b   Rötzer, Susanne ^a   Volkenandt, Matthias ^c   Tilgen, Wolfgang ^d   Linse, Ruthild ^e   Boettjer, Jörg ^f   Vogt, Thomas ^g   Spieth, Konstanze ^h   Eigentler, Thomas ⁱ   Brockmeyer, Norbert H ^j   Hinzpeter, Axel ^a   Hauschild, Axel ^b   Schaefer, Martin ^a,k  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d KLINIKEN ESSEN MITTE   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f HELIOS KLINIKUM ERFURT   (Germany)

^g KLINIKUM MINDEN   (Germany)

^h UNIVERSITY OF REGENSBURG   (Germany)

ⁱ GOETHE UNIVERSITY   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k RUHR UNIVERSITY BOCHUM   (Germany)

more..

Author keywords

Adherence; Depression; Interferon alpha; Melanoma; Side effect

Indexed keywords

ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENTAL DISEASE; MOOD CHANGE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SYMPTOM CHECKLIST 90; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; MOOD DISORDERS; PERSONALITY DISORDERS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SKIN NEOPLASMS;

EID: 74349126816     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b8bdb9     Document Type: Article

References (68)

1. Grob J, Dreno B, De La Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351:1905-1910.
2. Kirkwood J, Strawderman M, Ernstorff M, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Psychol. 1996;14:7-17.
3. Pehamberger H, Soyer H, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16:1425-1429.
4. Eggermont A, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon Alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366: 1189-1196.
5. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the american joint committee on cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
6. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29:241-252.
7. Cirelli R, Tyring S. Major therapeutic uses of interferons. Clin Immunother. 1995;3:27-87.
8. Williams C, Linch D. Interferon alpha 2a. Br. J. Hosp. Med. 1997;57:436-439.
9. Quesada J, Talpaz M, Rios A. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986;4:234-243.
10. Dusheiko G. Side effects of alpha interferon in hepatitis C. Hepatology. 1997;26:112-121.
11. Rifflet H, Vuillemin E, Oberti F, et al. Suicidal impulses in patients with chronic viral hepatitis C treated by alpha interferon. Gastroen Clin Biol. 1998;22:353-357. (Pubitemid 28182847)
12. Van Gool A, Kruit W, Engels F, et al. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci. 2003;25: 11-20.
13. Strite D, Valentine A, Meyers C. Manic episodes in two patients treated with interferon-alpha. J Neuropsych Clin N. 1997;9:273-276.
14. Schaefer M, Schwaiger M. Interferon-alpha-assoziierte psychische nebenwirkungen. Fortschr Neurol Psychiat. 2003;71:469-476.
15. Schaefer M, Engelbrecht M, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:731-746.
16. Valentine A, Meyers C, Kling M, et al. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998; 25:39-47.
17. Wichers M, Maes M. The psychoneuroimmuno-pathophysiol-ogy of cytokine-induced depression in humans. Int J Neurop-sychopharmacol. 2002;5:375-388.
18. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994;10:115-150.
19. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med. 1999;340:1370.
20. Raison C, Demetrashvili M, Capuron L, et al. Neuropsychia-tric adverse effects of Interferon alpha: recognition and management. CNS Drugs. 2005;19:105-123.
21. Capuron L, Ravaud A, Miller A, et al. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun. 2004;18:205-213.
22. Renault P, Hoofnagle J, Park Y, et al. Psychiatric complications of long-term interferon-alpha therapy. Arch Intern Med. 1987;147:1577-1580.
23. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis c treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-451.
24. Merimsky O, Chaitchik S. Neurotoxicity of interferon-alpha. Anticancer Drugs. 1992;3:567-570.
25. Beck A, Ward C, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
26. Richter P, Werner J, Heerlein A, et al. On the validity of the beck depression inventory a review. Psychopathology. 1998;31: 160-168.
27. Derogatis L, Cleary P. Factorial invariance across gender for the primary symptom dimensions of the SCL-90. Br J Soc Clin Psychol. 1977;16:347-356.
28. Schaefer M, Schmidt F, Horn M, et al. Depression during treatment with interferon alpha. Psychosomatics. 2004;45:176.
29. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun. 2003;17:119-124.
30. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46:991-998.
31. Trask P, Esper P, Riba M, et al. Psychiatric side effects of interferon therapy: prevalence proposed mechanisms and future directions. J Clin Oncol. 2000;18:2316-2326.
32. Yokoyama A, Kimura Y, Shigemura J. Psychiatric side effects of interferon. J Toxicol Sci. 1996;21:93-96.
33. Kirkwood J, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002;20:3703-3718.
34. Kirkwood J, Resnick G, Cole B. Efficacy, safety and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol. 1997;24:16-23.
35. Musselman D, Lawson D, Gumnick J, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966. (Pubitemid 32240314)
36. Capuron L, Gumnick J, Musselman D, et al. Neurobehaviour-al effects of interferon alpha in cancer patients; phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-652.
37. Caraceni A, Gangeri L, Martini C, et al. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer. 1998;83:482-489.
38. Davis G, Balart L, Schiff E, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med. 1989;321:1501-1506.
39. Cascinelli N, Belli F, MacKie R, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional lymph node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358:866-869.
40. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994;343:913-914.
41. Trask P, Paterson A, Esper P, et al. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psycho-Oncology. 2004;13:526-536.
42. Groth-Marnat G. The Handbook of Psychological Assessment. 2nd ed. New York: John Wiley & sons; 1990.
43. Kubler-Ross W. On Death and Dying. London: Tavistock Publications; 1969.
44. Herschbach P. Das "Zufriedenheitsparadox" in der Lebens-qualitatsforschung. Psychother Psych Med. 2002;52:141-151.
45. Flatten G, Junger S, Gunkel S, et al. Traumatische und psychosoziale Belastungen bei Patienten mit akuter Tumor-erkrankung. Psychother Psych Med. 2003;53:191-201.
46. Trask P, Paterson A, Hayasaka S, et al. Psychosocial characteristics of individuals wiith non-stage melanoma. J Clin Oncol. 2001;19:2844-2850.
47. Dalakas M, Mock V, Hawkins M. Fatigue: definitions, mechanisms, and paradigms for study. Semin Oncol. 1998;25:48-53.
48. Gohier B, Goeb J, Rannou-Dubas K, et al. Hepatitis C, alfa interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry. 2003;4: 115-118.
49. Koskinas J, Merkouraki P, Manesis E, et al. Assessment of depression in patients with chronic hepatitis: effect of inter-feron treatment. Dig Diss. 2002;20:284-288.
50. Fontana R, Schwartz S, Gebremariam A, et al. Emotional distress during interferon alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics. 2002;43: 378-385.
51. Kraus M, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C recieving interferon alpha-2B therapy. J Clin Psychiatry. 2003;64:708-714.
52. Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon alfa in patients affected by hepatitis C virus. J Affect Disord. 2002;72:237-241.
53. Miyaoka H, Otsubo T, Kamijima K, et al. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry. 1999;156:1120.
54. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis c receiving interferon-[alpha]-based immunotherapy are related to interferon-[alpha]-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86-90.
55. Van Gool A, Van Ojik H, Kruit W, et al. Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. Anticancer Drugs. 2004;15:587-591.
56. Van Gool A, Fekkes D, Kruit W, et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res. 2003;119:125-132.
57. Capuron L, Ravaud A, Neveu P, et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7:468-473.
58. Bannink M, Kruit W, Van Gool A, et al. Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29:109-114.
59. Wichers M, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha induced depression. J Psychiatry Neurosci. 2004;29:11-17.
60. Wichers M, Koek G, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005; 10:538-544.
61. Cai W, Khaoustov V, Xie Q, et al. Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol. 2005;42:880-887.
62. Felger J, Alagbe O, Hu F, et al. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry. 2007;62:1324-1333.
63. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokin network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001;105:45-55.
64. Friebe A, Schwarz M, Schmid-Wendtner M, et al. Pretreat-ment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J Immunother. 2007;30:333-337.
65. Schaefer M, Horn M, Schmidt F, et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav Immun. 2004; 18:555-562.
66. Schaefer M, Schwaiger M, Pich M, et al. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry. 2003;36(suppl 3):203-206.
67. Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics. 2000; 41:439-441.
68. Garbe C, Hauschild A, Volkenandt M, et al. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res. 2008;18:152-160.